Mirum Pharmaceuticals announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of LIVMARLI for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients three months of age and older.